+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07758023

Optimizing Medical Therapy with Early Percutaneous Repair of Secondary Mitral Regurgitation in Patients with Heart Failure and Reduced Ejection Fraction

Led by University Medical Center Mainz · Updated on 2026-11-02

520

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a treatment approach for patients with heart failure and reduced ejection fraction HFrEF who also have significant secondary mitral regurgitation. The trial aims to determine if early transcatheter edge-to-edge repair TEER of the mitral valve helps patients achieve faster and more complete guideline-directed medical therapy GDMT up-titration, and if this leads to better quality of life and clinical outcomes. Participants are randomly assigned to one of two groups. One group receives the TEER procedure within seven days of randomization followed by a structured GDMT up-titration regimen starting the day after the procedure. The other group receives the same GDMT regimen starting at randomization but without the early TEER. Medication doses are adjusted based on safety thresholds at several visits over 12 weeks. After 12 weeks, patients in the control group may opt to undergo TEER or mitral valve surgery if needed. During the study, participants undergo multiple assessments including evaluations of their medical therapy adherence, quality of life using the Kansas City Cardiomyopathy Questionnaire KCCQ, and clinical outcomes such as cardiovascular death or heart failure hospitalizations over 24 months. Medication safety and tolerability are carefully monitored at visits scheduled at 2, 4, 6, 8, 10, and 12 weeks. The trial lasts up to 24 months from randomization to assess the long-term impact of the treatments.

CONDITIONS

Brief Title

Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF

Research Team

K

Karl-Patrik Kresoja, MD

V

Vera Jakobi

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here